Cover Image
Market Research Report

Latin America, Middle East & Africa Cancer Immunotherapy Market (2018 - 2024)

Published by KBV Research Product code 763727
Published Content info 86 Pages
Delivery time: 1-2 business days
Price
Back to Top
Latin America, Middle East & Africa Cancer Immunotherapy Market (2018 - 2024)
Published: December 20, 2018 Content info: 86 Pages
Description

The Latin America, Middle East and Africa Cancer Immunotherapy Market would witness market growth of 15.5% CAGR during the forecast period (2018 - 2024). Cancer immunotherapy is the type of cancer treatment helping the immune system fight cancer. There are various kinds of cancer immunotherapies used and they are monoclonal antibody, therapeutic cancer vaccines, checkpoint inhibitors, cytokines, and others. Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market. Additionally, growing geriatric population and governmental contribution to healthcare expenditure are some other factors that add to the market growth.

Based on technology, the market is segmented into Monoclonal Antibodies, Cytokines & Immunomodulators and other technology. Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application. Based on end user the market is segmented into Hospitals, Clinics and other end user.

Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd

Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 LAMEA Cancer Immunotherapy Market, by Technology
    • 1.4.2 LAMEA Cancer Immunotherapy Market, by Application
    • 1.4.3 LAMEA Cancer Immunotherapy Market, by End User
    • 1.4.4 LAMEA Cancer Immunotherapy Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. LAMEA Cancer Immunotherapy Market by Technology

    • 3.1.1 LAMEA Monoclonal Antibodies Cancer Immunotherapy Market by Country
    • 3.1.2 LAMEA Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
    • 3.1.3 LAMEA Other Technology Cancer Immunotherapy Market by Country

Chapter 4. LAMEA Cancer Immunotherapy Market by Application

    • 4.1.1 LAMEA Cancer Immunotherapy Lung Cancer Market by Country
    • 4.1.2 LAMEA Cancer Immunotherapy Breast Cancer Market by Country
    • 4.1.3 LAMEA Cancer Immunotherapy Colorectal Cancer Market by Country
    • 4.1.4 LAMEA Cancer Immunotherapy Melanoma Market by Country
    • 4.1.5 LAMEA Cancer Immunotherapy Prostate Cancer Market by Country
    • 4.1.6 LAMEA Cancer Immunotherapy Head & Neck Cancer Market by Country
    • 4.1.7 LAMEA Other Application Cancer Immunotherapy Market by Country

Chapter 5. LAMEA Cancer Immunotherapy Market by End User

    • 5.1.1 LAMEA Hospitals Cancer Immunotherapy Market by Country
    • 5.1.2 LAMEA Clinics Cancer Immunotherapy Market by Country
    • 5.1.3 LAMEA Other End User Cancer Immunotherapy Market by Country

Chapter 6. LAMEA Cancer Immunotherapy Market by Country

  • 6.1 Brazil Cancer Immunotherapy Market
    • 6.1.1 Brazil Cancer Immunotherapy Market by Technology
    • 6.1.2 Brazil Cancer Immunotherapy Market by Application
    • 6.1.3 Brazil Cancer Immunotherapy Market by End User
  • 6.2 Argentina Cancer Immunotherapy Market
    • 6.2.1 Argentina Cancer Immunotherapy Market by Technology
    • 6.2.2 Argentina Cancer Immunotherapy Market by Application
    • 6.2.3 Argentina Cancer Immunotherapy Market by End User
  • 6.3 UAE Cancer Immunotherapy Market
    • 6.3.1 UAE Cancer Immunotherapy Market by Technology
    • 6.3.2 UAE Cancer Immunotherapy Market by Application
    • 6.3.3 UAE Cancer Immunotherapy Market by End User
  • 6.4 Saudi Arabia Cancer Immunotherapy Market
    • 6.4.1 Saudi Arabia Cancer Immunotherapy Market by Technology
    • 6.4.2 Saudi Arabia Cancer Immunotherapy Market by Application
    • 6.4.3 Saudi Arabia Cancer Immunotherapy Market by End User
  • 6.5 South Africa Cancer Immunotherapy Market
    • 6.5.1 South Africa Cancer Immunotherapy Market by Technology
    • 6.5.2 South Africa Cancer Immunotherapy Market by Application
    • 6.5.3 South Africa Cancer Immunotherapy Market by End User
  • 6.6 Nigeria Cancer Immunotherapy Market
    • 6.6.1 Nigeria Cancer Immunotherapy Market by Technology
    • 6.6.2 Nigeria Cancer Immunotherapy Market by Application
    • 6.6.3 Nigeria Cancer Immunotherapy Market by End User
  • 6.7 Rest of LAMEA Cancer Immunotherapy Market
    • 6.7.1 Rest of LAMEA Cancer Immunotherapy Market by Technology
    • 6.7.2 Rest of LAMEA Cancer Immunotherapy Market by Application
    • 6.7.3 Rest of LAMEA Cancer Immunotherapy Market by End User

Chapter 7. Company Profiles

  • 7.1 Amgen Inc.
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental & Regional Analysis
    • 7.1.4 Research and Development Expense
  • 7.2 Merck & Company, Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Regional and Segmental Analysis
    • 7.2.4 Research & Development
  • 7.3 Pfizer Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental &Regional Analysis
    • 7.3.4 Revenue analysis by Region
    • 7.3.5 Research and Development
  • 7.4 Immunomedics Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Revenue Analysis by Region
    • 7.4.4 Research and Development
  • 7.5 Astrazeneca Plc.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental analysis
    • 7.5.4 Research & Development
  • 7.6 F. Hoffmann-La Roche Ltd.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Revenue & Segment analysis
    • 7.6.4 Research and Development
  • 7.7 Eli Lilly and Company
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Segmental and Regional Analysis
    • 7.7.4 Research & Development Expense
  • 7.8 Novartis AG
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 Bristol-Myers Squibb Company
    • 7.9.1 Company Overview
  • 7.1 Bayer AG
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Segmental and Regional Analysis
    • 7.10.4 Research & Development Expense

LIST OF TABLES

  • TABLE 1 LAMEA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 2 LAMEA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 3 LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 4 LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 5 LAMEA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 6 LAMEA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 7 LAMEA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 8 LAMEA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 9 LAMEA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 10 LAMEA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 11 LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 12 LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 13 LAMEA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 14 LAMEA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 15 LAMEA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 16 LAMEA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 17 LAMEA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 18 LAMEA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 19 LAMEA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 20 LAMEA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 21 LAMEA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 22 LAMEA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 23 LAMEA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 24 LAMEA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 25 LAMEA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 26 LAMEA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 27 LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 28 LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 29 LAMEA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 30 LAMEA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 31 LAMEA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 32 LAMEA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 33 LAMEA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 34 LAMEA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 35 LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 36 LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 37 BRAZIL CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 38 BRAZIL CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 39 BRAZIL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 40 BRAZIL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 41 BRAZIL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 42 BRAZIL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 43 BRAZIL CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 44 BRAZIL CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 45 ARGENTINA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 46 ARGENTINA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 47 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 48 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 49 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 50 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 51 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 52 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 53 UAE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 54 UAE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 55 UAE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 56 UAE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 57 UAE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 58 UAE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 59 UAE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 60 UAE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 61 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 62 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 63 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 64 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 65 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 66 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 67 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 68 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 69 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 70 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 71 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 72 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 73 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 74 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 75 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 76 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 77 NIGERIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 78 NIGERIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 79 NIGERIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 80 NIGERIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 81 NIGERIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 82 NIGERIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 83 NIGERIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 84 NIGERIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 85 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 86 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 87 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 88 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 89 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 90 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 91 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 92 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 93 KEY INFORMATION-AMGEN INC.
  • TABLE 94 KEY INFORMATION-MERCK & COMPANY INC.
  • TABLE 95 KEY INFORMATION- PFIZER INC.
  • TABLE 96 KEY INFORMATION- IMMUNOMEDICS INC.
  • TABLE 97 KEY INFORMATION- ASTRAZENECA PLC.
  • TABLE 98 KEY INFORMATION- F. HOFFMANN-LA ROCHE LTD.
  • TABLE 99 KEY INFORMATION - ELI LILLY AND COMPANY
  • TABLE 100 KEY INFORMATION - NOVARTIS AG
  • TABLE 101 KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY
  • TABLE 102 KEY INFORMATION - BAYER AG
Back to Top